{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:42:26Z","timestamp":1787013746416,"version":"build-2736575974"},"reference-count":43,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2018,10,26]],"date-time":"2018-10-26T00:00:00Z","timestamp":1540512000000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#am"},{"start":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T00:00:00Z","timestamp":1508976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2017,11]]},"abstract":"Abstract<\/jats:title>\n \n Aim<\/jats:title>\n \n Tuberculosis screening is recommended for patients with immune\u2010mediated inflammatory diseases (\n IMID<\/jats:styled-content>\n s) prior to anti\u2010tumor necrosis factor (\n TNF<\/jats:styled-content>\n ) therapy. However, adherence to the recommended practice is unknown in the current clinical setting in Japan.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n We used a large\u2010scale health insurance claims database in Japan to conduct a longitudinal observational study. Of more than two million beneficiaries in the database between 2013 and 2014, we enrolled those with\n IMID<\/jats:styled-content>\n s aged 15\u201369 years who had initiated anti\u2010\n TNF<\/jats:styled-content>\n therapy. We defined tuberculosis screening primarily as tuberculin skin test and\/or interferon\u2010gamma release assay (\n TST<\/jats:styled-content>\n \/\n IGRA<\/jats:styled-content>\n ) within 2 months before commencing anti\u2010\n TNF<\/jats:styled-content>\n therapy. We analyzed the proportions of the patients who had undergone tuberculosis screening and the associations with primary disease, type of anti\u2010\n TNF<\/jats:styled-content>\n agent, methotrexate prescription prior to anti\u2010\n TNF<\/jats:styled-content>\n therapy, and treatment for latent tuberculosis infection (\n LTBI<\/jats:styled-content>\n ).\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 385 patients presumed to have initiated anti\u2010\n TNF<\/jats:styled-content>\n therapy, 252 (66%) had undergone tuberculosis screening by\n TST<\/jats:styled-content>\n \/\n IGRA<\/jats:styled-content>\n (22%\n TST<\/jats:styled-content>\n , 56%\n IGRA<\/jats:styled-content>\n , and 12% both\n TST<\/jats:styled-content>\n and\n IGRA<\/jats:styled-content>\n ), and 231 (60%) had undergone\n TST<\/jats:styled-content>\n \/\n IGRA<\/jats:styled-content>\n and radiography. Patients with psoriasis tended to be more likely to undergo tuberculosis screening than those with other diseases; however, this association was not statistically significant. Treatment for\n LTBI<\/jats:styled-content>\n was provided to 43 (11%) patients; 123 (32%) received neither\n TST<\/jats:styled-content>\n \/\n IGRA<\/jats:styled-content>\n nor\n LTBI<\/jats:styled-content>\n treatment.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n Tuberculosis screening was often not performed prior to anti\u2010\n TNF<\/jats:styled-content>\n therapy despite the guidelines\u2019 recommendations; thus, patients could be put at unnecessary risk of reactivation of tuberculosis.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/1756-185x.13190","type":"journal-article","created":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T22:26:41Z","timestamp":1509056801000},"page":"1674-1683","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Tuberculosis screening prior to anti\u2010tumor necrosis factor therapy among patients with immune\u2010mediated inflammatory diseases in Japan: a longitudinal study using a large\u2010scale health insurance claims database"],"prefix":"10.1111","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4686-0992","authenticated-orcid":false,"given":"Jun","family":"Tomio","sequence":"first","affiliation":[{"name":"Department of Public Health Graduate School of Medicine The University of Tokyo Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Yamana","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Health Economics Graduate School of Medicine The University of Tokyo Tokyo Japan"},{"name":"Health and Sanitation Department, Bunkyo City Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Matsui","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Health Economics Graduate School of Medicine The University of Tokyo Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Division of Rheumatic Diseases National Center for Global Health and Medicine Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yoshiyama","sequence":"additional","affiliation":[{"name":"Research Institute of Tuberculosis Tokyo Japan"},{"name":"Fukujuji Hospital Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Yasunaga","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Health Economics Graduate School of Medicine The University of Tokyo Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,10,26]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030275"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2007.10.030"},{"key":"e_1_2_7_4_1","article-title":"Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis","author":"Lawson MM","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006893"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011110"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1086\/421494"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21386"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00028510"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.13.0644"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(03)00545-0"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2015.03.003"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.043166"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-011-0541-5"},{"key":"e_1_2_7_15_1","unstructured":"Japan College of Rheumatology. (2012)Guidelines for TNF inhibitors treatment for rheumatoid arthritis(2012 revised version) (in Japanese)."},{"key":"e_1_2_7_16_1","unstructured":"Research Group for Intractable Inflammatory Bowel Diseases. (2013)Diagnosis criteria and clinical guidelines for ulcerative colitis and Crohn's disease(2012 revised version) (in Japanese)"},{"key":"e_1_2_7_17_1","unstructured":"Review Committee of Biologic Agents Japanese Dermatological Association. (2011)Treatment and safety guidelines for biologic agents for psoriasis(2011) (in Japanese)"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21641"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204573"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.01.011"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080791"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205376"},{"key":"e_1_2_7_23_1","first-page":"1","article-title":"Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor\u2010\u03b1 inhibitor","volume":"5521","author":"Byun JM","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.12.0029"},{"key":"e_1_2_7_25_1","unstructured":"World Health Organization.WHO TB burden estimates. Available from URL:https:\/\/www.extranet.who.int\/tme\/generateCSV.asp?ds=estimates. Accessed April 1 2017."},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002152"},{"key":"e_1_2_7_27_1","first-page":"28","article-title":"Changes in the management of rheumatoid arthritis at outpatients clinic in Osaka Prefecture: results of questionnaire surveys of members of the Osaka Clinical Orthopedic Association in 2003, 2008 and 2013 (in Japanese)","volume":"27","author":"Wada T","year":"2015","journal-title":"Clin Rheumatol Relat Res"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-012-0702-1"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.072967"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.2188\/jea.JE20090066"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2013.854059"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-013-2482-1"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.2188\/jea.13.127"},{"key":"e_1_2_7_34_1","unstructured":"Research Group for Intractable Inflammatory Bowel Disease. (2015)Diagnosis criteria and clinical guidelines for ulcerative colitis and Crohn's disease(2014 revised version) (in Japanese)."},{"key":"e_1_2_7_35_1","unstructured":"Japanese Respiratory Society ed. (2014)Biologic agents and respiratory diseases: clinical guidelines(in Japanese).Japanese Respiratory Society Tokyo."},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i11.3308"},{"key":"e_1_2_7_37_1","unstructured":"Ministry of Health Labour and Welfare. (2015)Outline of survey on medical facilities(in Japanese)."},{"key":"e_1_2_7_38_1","unstructured":"World Health Organization.Guidelines on the management of latent tuberculosis infection. Available from URL:http:\/\/AppsWhoInt\/Iris\/Bitstream\/10665\/136471\/1\/9789241548908_EngPdf?Ua=1&Ua=1. 2015:38. Accessed April 1 2017."},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2015.1064470"},{"key":"e_1_2_7_40_1","article-title":"QuantiFERON\u2010TB Gold In\u2010Tube assay for screening arthritis patients for latent tuberculosis infection before starting anti\u2010tumor necrosis factor treatment","author":"Lee H","year":"2015","journal-title":"PLoS ONE"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu796"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-007-0626-3"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.13.0755"},{"key":"e_1_2_7_44_1","unstructured":"The Tuberculosis Surveillance Center. (2015)Annual reports 2015: prevalence of tuberculosis (per 100 000) prefecture and major cities (2008\u20132015). Available from URL:http:\/\/www.jata.or.jp\/rit\/ekigaku\/index.php\/download_file\/-\/view\/3707\/. Accessed April 1 2017."}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.13190","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.13190","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1756-185X.13190","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/am-pdf\/10.1111\/1756-185X.13190","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.13190","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T02:46:21Z","timestamp":1694313981000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.13190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,26]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.1111\/1756-185X.13190"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.13190","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,26]]},"assertion":[{"value":"2017-10-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}